This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2025
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2025 | 990 | $4,224,824 | $3,730,243 | $1,695,918 | $3,683,169 | $1,711,921 |
| FY2024 | 990 | $1,384,349 | $1,912,526 | $914,813 | $2,928,993 | $1,190,249 |
| FY2023 | 990 | $3,984,492 | $3,727,170 | $2,040,951 | $3,305,936 | $1,729,963 |
| FY2022 | 990 | $3,117,985 | $4,187,668 | $2,568,802 | $3,281,205 | $1,464,352 |
| FY2021 | 990 | $2,821,956 | $3,066,121 | $2,078,326 | $3,627,407 | $2,534,035 |
| FY2020 | 990 | $3,233,755 | $2,711,990 | $1,962,656 | $3,134,004 | $2,778,200 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 89% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| NEW YORK MEDICAL COLLEGEVALHALLA, NY | PEDIATRIC CANCER RESEARCH FOUNDATION LABORATORY AT NYMC | $900,000 | 2022 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Steve Giusto | PRESIDENT | 1.00 | $0 |
| John Coon | VICE PRESIDENT | 1.00 | $0 |
| Scott Ecker | TREASURER | 1.00 | $0 |
| Beth Abrams | DIRECTOR |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| NEW YORK MEDICAL COLLEGEVALHALLA, NY |
| PEDIATRIC CANCER RESEARCH LABORATORY GRANT |
| $862,160 |
| 2021 |
| NEW YORK MEDICAL COLLEGEVALHALLA, NY | PEDIATRIC CANCER RESEARCH LABORATORY GRANT | $667,840 | 2020 |
| NEW YORK MEDICAL COLLEGEVALHALLA, NY | PEDIATRIC CANCER RESEARCH FOUNDATION LABORATORY AT NEW YORK MEDICAL COLLEGE | $550,000 | 2025 |
| NEW YORK MEDICAL COLLEGEVALHALLA, NY | PEDIATRIC CANCER RESEARCH FOUNDATION LABORATORY AT NEW YORK MEDICAL COLLEGE | $550,000 | 2023 |
| ANN & ROBERT LURIE CHILDREN'S HOSPITALCHICAGO, IL | RESEARCH INTO THE EPIGENETIC TARGETED THERAPY FOR PEDIATRIC MALIGNANT GLIOMA-BROMODOMAIN INHIBITOR | $296,250 | 2020 |
| NEW YORK MEDICAL COLLEGEVALHALLA, NY | PEDIATRIC CANCER RESEARCH FOUNDATION LABORATORY AT NEW YORK MEDICAL COLLEGE | $275,000 | 2024 |
| V FOUNDATIONCARY, NC | CANCER RESEARCH | $204,000 | 2025 |
| DANA-FARBER CANCER INSTITUTEBOSTON, MA | RESEARCH INTO THE PROSPECTIVE VALIDATION OF A PROGNOSTIC LIQUID BIOPSY APPROACH FOR PEDIATRIC EWING SARCOMA | $168,000 | 2020 |
| MEMORIAL SLOAN KETTERINGNEW YORK, NY | TOWARDS CURATIVE EPIGENETIC THERAPIES OF REFRACTORY PEDIATRIC SARCOMAS | $150,000 | 2025 |
| MEMORIAL SLOAN KETTERINGNEW YORK, NY | TOWARDS CURATIVE EPIGENETIC THERAPIES OF REFRACTORY PEDIATRIC SARCOMAS | $150,000 | 2023 |
| UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTERHOUSTON, TX | COMBINING A NOVEL DENDRITIC CELL VACCINE WITH CHECKPOINT BLOCKADE FOR OSTEOSARCOMA THERAPY | $125,000 | 2022 |
| UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTERHOUSTON, TX | BASIC RESEARCH SCIENCE GRANT COMBINING A NOVEL DENDRITIC CELL VACCINE WITH CHECKPOINT BLOCKADE FOR OSTEOSARCOMA THERAPY | $125,000 | 2021 |
| SEATTLE CHILDREN'S HOSPITALSEATTLE, WA | BASIC RESEARCH SCIENCE GRANT DEVELOPMENT OF TUNABLE ON-OFF CAR T CELLS FOR SAFE AND DURABLE TUMOR CONTROL | $125,000 | 2021 |
| STANFORD UNIVERSITYPALO ALTO, CA | BASIC RESEARCH SCIENCE GRANT DEVELOPMENT OF SMALL MOLECULES TO TARGET CREB:CBP INTERACTION FOR TREATMENT OF AML | $125,000 | 2021 |
| CHILDREN'S HOSPITAL OF PHILADELPHIA RESEARCH INSTITUTEPHILADELPHIA, PA | BASIC RESEARCH SCIENCE GRANT PRECISION MEDICINE TO EXPLOIT BCL2-FAMILY SURVIVAL DEPENDENCIES IN NEUROBLASTOMA | $125,000 | 2021 |
| TEXAS CHILDREN'S HOSPITALHOUSTON, TX | RESEARCH INTO MOLECULAR CHARACTERIZATION OF UNDIFFERENTIATED SARCOMAS | $125,000 | 2021 |
| CHILDREN'S HOSPITAL OF PHILADELPHIAPHILADELPHIA, PA | PRECISION MEDICINE TO EXPLOIT BCL2-FAMILY SURVIVAL DEPENDENCIES IN NEUROBLASTOMA | $125,000 | 2022 |
| UNIVERSITY OF CALIFORNIA SAN FRANCISCOSAN FRANCISCO, CA | MODULATING THE IMMUNE MICROENVIRONMENT IN PEDIATRIC ACUTE MYELOID LEUKEMIA | $115,000 | 2022 |
| STANFORD UNIVERSITYPALO ALTO, CA | TARGETING MITOCHONDRIAL PATHWAYS IN PEDIATRIC AML | $115,000 | 2023 |
| UCSFSAN FRANCISCO, CA | TACL2020-004: A RISK STRATIFIED CLINICAL TRIAL FOR PATIENTS WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA | $115,000 | 2023 |
| CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINECLEVELAND, OH | BASIC RESEARCH SCIENCE AWARD FOR THERAPY OF OSTEOSARCOMA PULOMARY METASTASIS | $105,000 | 2020 |
| DANA FARBERBOSTON, MA | PROSPECTIVE VALIDATION OF A PROGNOSTIC LIQUID BIOPSY APPROACH FOR PEDIATRIC EWING SARCOMA | $105,000 | 2023 |
| STANFORDPALO ALTO, CA | TARGETING MITOCHONDRIAL PATHWAYS IN PEDIATRIC AML | $100,000 | 2025 |
| CITY OF HOPEDUARTE, CA | SINGLE-CELL DISSECTING OF HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | $100,000 | 2025 |
| 1.00 |
| $0 |
| Susie Buchan | DIRECTOR | 1.00 | $0 |
| Tim Cromwell | DIRECTOR | 1.00 | $0 |
| Cherie Daly | DIRECTOR | 1.00 | $0 |
| Keith Koeller | DIRECTOR | 1.00 | $0 |
| Elizabeth Mcnulty | DIRECTOR | 1.00 | $0 |
| Jason O'Donnell | DIRECTOR | 1.00 | $0 |
| Amanda Saratsis Md | DIRECTOR | 1.00 | $0 |
| John Vallely | DIRECTOR | 1.00 | $0 |
| Darth Vaughn | DIRECTOR | 1.00 | $0 |
| John Weiner | DIRECTOR | 1.00 | $0 |
| Nicole Wilkins | DIRECTOR | 1.00 | $0 |
| Len Shulman | DIRECTOR | 1.00 | $0 |
| Jeri Willson | EXECUTIVE DIRECTOR (THRU 10/2024) | 40.00 | $188,813 |
| Danielle Fragalla | CEO | 40.00 | $202,223 |
| Morgan March | SENIOR DIRECTOR OF DEVELOPMENT | 40.00 | $115,704 |
| Bonnie Lattimore | VP OF DEVELOPMENT, STRAT. PTNRSHP | 40.00 | $115,038 |
| Savannah Schmier | SPECIAL EVENTS MANAGER | 40.00 | $107,508 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990 · FY2024 · period ending Jun 30, 2024IRS bulk XML
Filing id 202521079349301112
Form 990 · FY2023 · period ending Dec 31, 2023IRS bulk XML
Filing id 202402729349300305
Form 990 · FY2022 · period ending Dec 31, 2022
Filing id 202322719349302127
Form 990 · FY2021 · period ending Dec 31, 2021
Filing id 202202729349301750
Form 990 · FY2020 · period ending Dec 31, 2020
Filing id 202132789349300548
Form 990 · FY2018 · period ending Dec 31, 2018
Filing id 201913019349301186
Form 990 · FY2017 · period ending Dec 31, 2017
Filing id 201822089349300322
Form 990 · FY2016 · period ending Dec 31, 2016
Filing id 201743539349300974
Form 990 · FY2015 · period ending Dec 31, 2015
Filing id 201642539349300839
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.